 Focused on lead anti-inflammatory drug FSD-201 Launched Phase 2 study of drug known as micro PEA in December 2020 Developing drugs to treat gastrointestinal diseases in dogs and cats What FSD Pharma does: FSD Pharma Inc NASDAQ:HUGE CSE:HUGE is a publicly-traded holding company that owns subsidiary FSD Pharma BioSciences Inc, a specialty biotech pharmaceutical RD firm focused on developing multiple applications of its lead anti-inflammatory drug FSD-201. The drug is now one of several therapeutics being advanced that could help reduce severe and deadly lung infection in coronavirus COVID-19 patients. 